Cargando…
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
BACKGROUND AND OBJECTIVE: In our outpatient pediatric and adult psychiatry centers, we reserve psychostimulants for predominantly inattentive attention deficit hyperactivity disorder (ADHD) due to the potential for appetite and growth suppression, insomnia, wear off, exacerbation of mood, anxiety, a...
Autores principales: | Price, Maxwell Z., Price, Richard L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374479/ https://www.ncbi.nlm.nih.gov/pubmed/37430151 http://dx.doi.org/10.1007/s40263-023-01023-6 |
Ejemplares similares
-
Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”
por: Price, Maxwell Z., et al.
Publicado: (2023) -
Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021) -
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2021) -
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)